Alexion-Section-1-Heading
Alexion-Section-1-Cell
Alexion-Section-1-Cell
Alexion-Section-1

PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA (PNH)

is a rare, life-threatening condition driven by complement-mediated intravascular haemolysis.1-3
Reaching a diagnosis of PNH may be delayed due its rarity and the overlap of symptoms with other conditions.1
If you suspect PNH, the diagnostic pathway on this website may be a useful guide to follow.

Alexion-Section-3
Alexion-Section-4

Adapted from Roth A et al. 2018.1 aParker 2005; bPeffault de Latour 2008, Brodsky 2009, Valent 2012; cNICE 2015. An unexplained persistent cytopaenia in patients in whom (minimal) diagnostic criteria for MDS are not fulfilled. *DVT and/or PE in a patient with no antecedent major clinical risk factor for VTE that is not provoked by surgery, trauma, immobilisation, hormonal therapy (oral contraceptive or hormone replacement therapy) or active cancer. **Unusual sites include hepatic veins (Budd Chiari syndrome), other splanchnic veins (portal, splenic) cerebral vein and dermal veins.1

DVT: deep vein thrombosis; FLAER: fluorescein-labelled proaerolysin; LDH: lactate dehydrogenase; MDS: myelodysplastic syndrome; PE: pulmonary embolism; VTE: venous thromboembolism.

THE PNH MANAGEMENT CYCLE

2,3
Alexion-Section-5

THE PATH TO DIAGNOSING PNH MAY BE COMPLICATED,
BUT THE TREATMENT DOESN’T NEED TO BE.

Alexion-Section-6
If you are a healthcare professional and you'd like to learn more about the diagnosis, management and treatment of PNH, please contact Alexion using the form below:
View privacy statement
For Medical Information, please email Alexion at medicalinformation.australasia@alexion.com
For Pharmacovigilance, please email Alexion at pharmacovigilance.australasia@alexion.com
References: 1. Roth A et al. Eur J Haematol 2018;1-9. 2. Borowitz MJ et al. Cytometry B Clin Cytom 2010;78:211–230. 3. Parker C et al. Blood 2005;106:3699–3709.
Alexion-Contact-Form-Background